FMC Dialysis - Livonia is a medicare approved dialysis facility center in Livonia, Michigan and it has 20 dialysis stations. It is located in Wayne county at 32423 Schoolcraft Rd, Livonia, MI, 48150. You can reach out to the office of FMC Dialysis - Livonia at (734) 525-0780. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Dialysis - Livonia has the following ownership type - Profit. It was first certified by medicare in September, 1977. The medicare id for this facility is 232501 and it accepts patients under medicare ESRD program.
| Name | FMC Dialysis - Livonia |
|---|---|
| Location | 32423 Schoolcraft Rd, Livonia, Michigan |
| No. of Dialysis Stations | 20 |
| Medicare ID | 232501 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 32423 Schoolcraft Rd, Livonia, Michigan, 48150 | |
| (734) 525-0780 | |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
| NPI Number | 1639284490 |
| Organization Name | Bma Livonia |
| Doing Business As | Bio-medical Applications Of Michigan, Inc. |
| Address | 32423 Schoolcraft Rd Livonia, Michigan, 48150 |
| Phone Number | (734) 525-0780 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 58% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 15% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 27% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 37% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 14% |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 45% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 35% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 38% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 36% | 12% |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 65% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 35% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 43% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 12% |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 40 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 20 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 91 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 733 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Dialysis - Livonia with elevated calcium levels.
| Patients with hypercalcemia | 96 |
| Hypercalcemia patient months | 784 |
| Patients with Serumphosphor | 105 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 39 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 89 |
| Patient months included in arterial venous fistula and catheter summaries | 558 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 57 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 17 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 92 |
| Hospitalization Rate in facility | 238.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 357.5 |
| Hospitalization Rate: Lower Confidence Limit | 162.4 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Dialysis - Livonia were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 28.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 38.6 |
| Readmission Rate: Lower Confidence Limit | 19.4 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Dialysis - Livonia get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .55 (As Expected) |
| SIR: Upper Confidence Limit | 1.32 |
| SIR: Lower Confidence Limit | .17 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Dialysis - Livonia's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 74 |
| Transfusion Rate in facility | 28.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 77 |
| Transfusion Rate: Lower Confidence Limit | 12.2 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Dialysis - Livonia lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 531 |
| Mortality Rate in facility | 17.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 22.1 |
| Mortality Rate: Lower Confidence Limit | 14.3 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago
Univ Of Mi Dialysis Clinics - Livonia Location: 19900 Haggerty Rd, Suite 106, Livonia, Michigan, 48152 Phone: (734) 432-7870 |
News Archive
Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.
Disturbances in the early stages of brain growth, such as preterm birth - when many of the brain's structures have not yet fully developed - appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
The Canadian Nurses Association (CNA) and the Canadian Medical Association (CMA) today announced the recipients of the 2010 Media Awards for Health Reporting, Canada's premier health journalism awards.
Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.
› Verified 4 days ago